Bruce Booth sold $2.4M of SION
director at Sionna Therapeutics, Inc.. 78,693 shares at an average of $30.08, traded Sep 29, 2025, filed Oct 1, 2025.
Score components
- +15RoleDirector
- +25Trade size$2.4M at market
- 0Share of holdings soldSold 2.7% of holdings
- +8Cluster2 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001451612-25-000004, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Sep 29, 2025 | SOpen-market sale Common Stockindirect: By Atlas Venture Fund XI, L.P.10b5-1 | -54,637 | $30.09 | $1.6M | 2,831,656 | Oct 1, 2025 |
| Sep 29, 2025 | SOpen-market sale Common Stockindirect: By Atlas Venture Opportunity Fund II, L.P.10b5-1 | -11,468 | $30.09 | $345k | 796,259 | Oct 1, 2025 |
| Sep 30, 2025 | SOpen-market sale Common Stockindirect: By Atlas Venture Fund XI, L.P.10b5-1 | -10,239 | $30.06 | $308k | 2,821,417 | Oct 1, 2025 |
| Sep 30, 2025 | SOpen-market sale Common Stockindirect: By Atlas Venture Opportunity Fund II, L.P.10b5-1 | -2,149 | $30.06 | $65k | 794,110 | Oct 1, 2025 |
| Oct 1, 2025 | SOpen-market sale Common Stockindirect: By Atlas Venture Fund XI, L.P.10b5-1 | -165 | $29.95 | $4,942 | 2,821,252 | Oct 1, 2025 |
| Oct 1, 2025 | SOpen-market sale Common Stockindirect: By Atlas Venture Opportunity Fund II, L.P.10b5-1 | -35 | $29.95 | $1,048 | 794,075 | Oct 1, 2025 |
Related signals
Other insiders at Sionna Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 50Moderate | SIONsell Sionna Therapeutics, Inc. | Ra Capital Management, L.p. director, owner | $22M 3,448,811 shares | -50% | |
| 28Weak | Sionna Therapeutics, Inc. | Orbimed Advisors LLC director | $1.5M 33,356 shares | -1% | |
| 28Weak | Sionna Therapeutics, Inc. | Peter A. Thompson director | $1.5M 33,356 shares | -1% | |
| 19Weak | Sionna Therapeutics, Inc. | Orbimed Advisors LLC director | $83k 1,875 shares | -0% | |
| 19Weak | Sionna Therapeutics, Inc. | Peter A. Thompson director | $83k 1,875 shares | -0% | |
| 31Weak | Sionna Therapeutics, Inc. | Jennifer Fitzpatrick Chief Legal Officer | $415k 10,250 shares | -100% | |
| 35Weak | Sionna Therapeutics, Inc. | Orbimed Advisors LLC director | $4.8M 108,073 shares | -3% | |
| 35Weak | Sionna Therapeutics, Inc. | Peter A. Thompson director | $4.8M 108,073 shares | -3% | |
| 55Moderate | Sionna Therapeutics, Inc. | Ra Capital Management, L.p. director, owner | $1.2M 30,316 shares | -0% | |
| 55Moderate | Sionna Therapeutics, Inc. | Ra Capital Management, L.p. director, owner | $5.5M 136,351 shares | -2% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.